
    
      The treatment period is composed of a 24-week double-blind period (Phase A) and a 28-week
      open-label period (Phase B). Participants will receive in Phase A: omarigliptin 25 mg once
      weekly, sitagliptin 50 mg once daily or placebo and in Phase B: omarigliptin 25 mg once
      weekly.
    
  